GLP-1 receptor agonists are licensed for type 2 diabetes and weight management, not specifically for cholesterol reduction
Seino, S., Shibasaki, T
In large studies, GLP-1 therapies reduced body weight by an average of 4.57 kg, body mass index by 2.07 kg/m, and waist circumference by 4.55 cm compared with placebo
GLP-1 RA medications, such as semaglutide (sold under the brand names Ozempic, Wegovy, and Rybelsus) slow gastric emptying, the rate at which food moves from your stomach to your small intestine
For March and April 2026, we examined semaglutide, tirzepatide, antidiabetic, and antibiotic product categories to identify shipments tied to unregistered facilities, product-code mismatches, active pharmaceutical ingredient imports, and shipments intended for compounding
If you spot a mistake, please let us know.